Bibliography
- Ma JD, Heavey SF, Revta C, Roeland EJ. Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther 2014;14(8):1113-20
- Molfino A, Laviano A, Rossi Fanelli F. Contribution of anorexia to tissue wasting in cachexia. Curr Opin Support Palliat Care 2010;4:249-53
- Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95
- Balstad TR, Kaasa S, Solheim TS. Multimodal nutrition/anabolic therapy for wasting conditions. Curr Opin Clin Nutr Metab Care 2014;17:226-35
- Clarke SJ, Gebbie C, Sweeney C, et al. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2010;1:98
- Schuster M, Rigas JR, Orlov SV, et al. ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II, randomized, double-blind, placebo-controlled trial. J Clin Oncol 2010;28:7622
- A study using MABp1 to increase overall survival in patients with colorectal cancer and weight loss 2014; Available from: http://clinicaltrials.gov/ct2/show/NCT01767857?term=MABp1&rank=1 [Last accessed 11 December 2013]
- Paspaliaris V, Langan B, DeAndrea R, et al. Phase I/II study of IP-1510 a novel interleukin-1 receptor antagonist in the management of cancer-related cachexia. J Cachexia Sarcopenia Muscle 2011;2:261
- Chasen MR, Bhargava R, Hirschman SZ, Taraporewala I. Phase II study of OHR/AVR118 in anorexia-cachexia. J Cachexia Sarcopenia Muscle 2013;4:335
- Costelli P, Muscaritoli M, Bonetto A, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008;38:531-8
- Bonetto A, Penna F, Aversa Z, et al. Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. Muscle Nerve 2013;48:387-92
- Aversa Z, Bonetto A, Penna F, et al. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 2012;19:1350-6
- Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 2014;34:606-18
- Hui D, De La Cruz M, Mori M, et al. Concepts and definitions for “supportive care”, “best supportive care”, “palliative care”, and “hospice care” in the published literature, dictionaries, and textbooks. Support Care Cancer 2013;21:659-85
- Lester JF, Agulnik J, Akerborg O, et al. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients? – Results from the lung cancer economics and outcomes research (LUCEOR) study. Lung Cancer 2013;82:128-35
- Gagnon B, et al. A prospective evaluation of an interdisciplinary nutrition-rehabilitation program for patients with advanced cancer. Curr Oncol 2013;20:310-18
- Muscaritoli M, Molfino A, Gioia G, et al. The “Parallel pathway”: a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med 2011;6:105-12
- Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-43
- Laviano A, Seelaender M, Sanchez-Lara K, et al. Beyond anorexia-cachexia. Nutrition and modulation of cancer patients’ metabolism: supplementary, complementary or alternative anti-neoplastic therapy? Eur J Pharmacol 2011;668:S87-90